- Home
- PAVM vs ENSC Comparison
PAVM vs ENSC Comparison
Compare PAVM & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- ENSC
- Stock Information
- Founded
- PAVM 2014
- ENSC 2003
- Country
- PAVM United States
- ENSC United States
- Employees
- PAVM N/A
- ENSC N/A
- Industry
- PAVM Medical/Dental Instruments
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- ENSC Health Care
- Exchange
- PAVM Nasdaq
- ENSC Nasdaq
- Market Cap
- PAVM 8.2M
- ENSC 7.9M
- IPO Year
- PAVM 2016
- ENSC N/A
- Fundamental
- Price
- PAVM $0.61
- ENSC $3.90
- Analyst Decision
- PAVM Strong Buy
- ENSC
- Analyst Count
- PAVM 1
- ENSC 0
- Target Price
- PAVM $19.00
- ENSC N/A
- AVG Volume (30 Days)
- PAVM 211.5K
- ENSC 15.7K
- Earning Date
- PAVM 03-25-2025
- ENSC 03-10-2025
- Dividend Yield
- PAVM N/A
- ENSC N/A
- EPS Growth
- PAVM N/A
- ENSC N/A
- EPS
- PAVM 0.53
- ENSC N/A
- Revenue
- PAVM $4,034,000.00
- ENSC $5,210,031.00
- Revenue This Year
- PAVM $52.90
- ENSC N/A
- Revenue Next Year
- PAVM $248.84
- ENSC N/A
- P/E Ratio
- PAVM $1.12
- ENSC N/A
- Revenue Growth
- PAVM 166.27
- ENSC 133.58
- 52 Week Low
- PAVM $0.57
- ENSC $2.12
- 52 Week High
- PAVM $2.84
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- PAVM 38.86
- ENSC 25.59
- Support Level
- PAVM $0.59
- ENSC $4.85
- Resistance Level
- PAVM $0.70
- ENSC $5.72
- Average True Range (ATR)
- PAVM 0.06
- ENSC 0.39
- MACD
- PAVM -0.02
- ENSC -0.05
- Stochastic Oscillator
- PAVM 8.61
- ENSC 2.99
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.